SAN DIEGO --(BUSINESS WIRE)--
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced the launch of Sensum+® in the U.S. An estimated 10-20 million men suffer from reduced penile sensitivity in the U.S. due to diabetes complications according to the National Institutes of Health (NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90. The neuropathy of erectile dysfunction, Nature, December 2002, Volume 14, Number 6, Pages 433-439). That represents an estimated market of more than $1 billion per year.
The product will be available through www.sensumplus.com and through the Beyond Human print and online platform targeting between 20-30 million Americans on a monthly basis.
As previously announced, Sensum+® was tested in human survey use clinical trial in circumcised men with low penile sensitivity.
We believe that results from the study showed statistically significant increases in all endpoints measured including:
- 197% in penile sensitivity
- 60% reduction in time for Masturbation Ejaculatory Latency Time (MELT) in diabetic men
- Over 300% increase in satisfaction
- Close to 275% increase in Partner’s Satisfaction
We believe that the data also indicates that Sensum+® was well tolerated with no serious adverse events reported.
Sensum+® is a proprietary patented topical formulation specifically designed to increase penile sensitivity in-licensed from Centric Research Institute.
“Sensum+® is the third Innovus product to be launched using our acquired Beyond Human sales and marketing platform and we currently believe the product could generate close to $2 million a year in revenues, adding to the revenues already being generated by the success of our Vesele® and RecalMax™ dietary supplements,” said Innovus CEO Dr. Bassam Damaj.
About Sensum+® and Reduced Penile Sensitivity (RPS)
Sensum+® is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+® (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+® was evaluated in two post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for 14 consecutive days followed by once daily for eight weeks and as needed thereafter.
Reduced penile sensitivity is a major problem associated with many diseases such as hernia surgery, the use of anti-depressants, circumcision, multiple sclerosis and others. There are no approved products to treat RPS.
For more information, visit www.sensumplus.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (h) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (i) BTH Vision Formula, (j) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Sensum+® product, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.